Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards. The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES “Best of Innovation” category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can be […]
Diabetes
7 diabetes treatment innovations to look out for on World Diabetes Day
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes. This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease. Some of those treatments involve insulin, which was discovered as a treatment for diabetes in […]
Senseonics posts Q3 earnings beat, hopes for new FDA approval soon
Senseonics (NYSE:SENS) shares ticked up slightly on third-quarter results that beat the consensus earnings forecast. The Germantown, Maryland-based company posted profits of $42.9 million, or 8¢ per share, on sales of $3.5 million for the three months ended Sept. 30, 2021, for a massive bottom-line swing out of the red on sales growth of nearly […]
Abbott, American Diabetes Association partner to help people of color with diabetes
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced today that they launched a joint community health partnership in Ohio. The community initiative — the first under the ADA’s Health Equity Now platform — will launch in Columbus, Ohio, and be conducted with the National Center for Urban Solutions (NCUS) in an effort to better […]
Insulet posts Q3 sales beat, remains on track for Omnipod 5 clearance
Insulet (NSDQ:PODD) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth […]
Tandem nosedives after hours despite strong Q3, raised guidance
Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast. TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%. The […]
Prime Therapeutics to prefer Viatris’ interchangeable insulin biosimilar
Pharmacy benefit manager Prime Therapeutics announced today that it will prefer Viatris’ (NSDQ:VTRS) Semglee insulin biosimilar injection on its national formularies as part of the pharmacy benefit. In July, the FDA cleared the Semglee insulin glargine-yfgn injection, developed by Viatris in collaboration with Biocon Biologics, as a biosimilar for controlling high blood sugar in adults […]
Dexcom enlists celebrities to promote The Global Movement for Time in Range
Dexcom (NSDQ:DXCM) announced today that it will utilize some star power to boost The Global Movement for Time in Range. Musician, actor and philanthropist Nick Jonas, along with musician, actress, author and entrepreneur Patti LaBelle, will both use their platforms to promote the initiative The Global Movement for Time in Range was launched earlier this […]
Dexcom raises guidance ahead of G7 launch, FDA submission imminent
Dexcom (NYSE:DXCM) shares are up more than 9% today — a day after the company announced it will soon formally seek FDA clearance for its next-gen G7 system. The San Diego-based diabetes management technology developer yesterday evening posted profits of $70.9 million, or 71¢ per share, on sales of $650.2 million for the three months […]
Better Therapeutics closes SPAC merger, debuts on Nasdaq
Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to […]